期刊
NATURE COMMUNICATIONS
卷 9, 期 -, 页码 -出版社
NATURE PUBLISHING GROUP
DOI: 10.1038/s41467-018-06354-3
关键词
-
资金
- Terry Fox Research Institute [1043]
- Genome Canada
- Genome British Columbia
- Canadian Institutes for Health Research
- British Columbia Cancer Foundation
- Terry Fox New Investigator Award [1021]
- Canadian Institutes for Health Research (CIHR) from CIHR
- Michael Smith Foundation for Health Research Scholar award
- Canada Research Chairs program
- CIHR Foundation grant [FDN-143288]
- Carlos Slim Health Institute
- Mildred-Scheel-Cancer-Foundation (German Cancer Aid)
- MSFHR
- Lymphoma Canada
Diffuse large B-cell lymphoma (DLBCL) is an aggressive cancer originating from mature B-cells. Prognosis is strongly associated with molecular subgroup, although the driver mutations that distinguish the two main subgroups remain poorly defined. Through an integrative analysis of whole genomes, exomes, and transcriptomes, we have uncovered genes and non-coding loci that are commonly mutated in DLBCL. Our analysis has identified novel cis-regulatory sites, and implicates recurrent mutations in the 3' UTR of NFKBIZ as a novel mechanism of oncogene deregulation and NF-kappa B pathway activation in the activated B-cell (ABC) subgroup. Small amplifications associated with over-expression of FCGR2B (the Fc gamma receptor protein IIB), primarily in the germinal centre B-cell (GCB) subgroup, correlate with poor patient outcomes suggestive of a novel oncogene. These results expand the list of subgroup driver mutations that may facilitate implementation of improved diagnostic assays and could offer new avenues for the development of targeted therapeutics.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据